Clarus Therapeutics (CLRS) Sees IPO Price of $11 - $13/Share
Tweet Send to a Friend
Clarus Therapeutics (Nasdaq: CLRS) filed a registration statement with the U.S. Securities and Exchange Commission today for an Initial Public Offering of their Common Stock. The company plans on offering 5,000,000 shares and sees a price of $11 to $13 per Share. The company has filed to list on the NASDAQ Global Market under the ticker "CLRS."
The offering is being made through Piper Jaffray, Wells Fargo Securities, Lazard Capital Markets, and Needham & Company, LLC.
Clarus is a pharmaceutical company focused on the development and commercialization of OriTex, our Phase III-ready oral testosterone, or T, replacement therapy.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The offering is being made through Piper Jaffray, Wells Fargo Securities, Lazard Capital Markets, and Needham & Company, LLC.
Clarus is a pharmaceutical company focused on the development and commercialization of OriTex, our Phase III-ready oral testosterone, or T, replacement therapy.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- GDC Technology (GDCT) Files $75M IPO
- Noodles & Co. Files (NDLS) Files $75M IPO
- Ply Gem (PGEM) IPO Opens Higher
Create E-mail Alert Related Categories
IPOsRelated Entities
Piper Jaffray, Needham & Company, Lazard
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
